Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LDN-603
- Development stage
- Unknown
- Lead developer
- Ladon Therapeutics
- Modality
- Peptides
- Administration
- Oral
01
Overview
LDN-603 is a first-in-class oral peptide mimic developed by Ladon Therapeutics that acts as a Glucagon-like peptide 1 (GLP-1) receptor agonist. Designed for the treatment of obesity and metabolic diseases, LDN-603 aims to provide the therapeutic benefits of GLP-1 receptor activation—such as improved glycemic control and weight reduction—through a convenient oral delivery system. This approach seeks to overcome the limitations of traditional injectable GLP-1 therapies, potentially enhancing patient compliance and broadening access to treatment. As of the latest pipeline information, LDN-603 is in Phase 1 clinical development.
02
Targets
Beyond the preview
Go deeper on LDN-603.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LDN-603.